How did the updated 2019 european society of cardiology/european atherosclerosis society risk categorization for patients with diabetes affect the risk perception and lipid goals, a simulated analysis of real-life data from EPHESUS study

Basit Öğe Kaydı
dc.authorid0000-0002-6384-6455
dc.authorid0000-0003-1836-2846
dc.authorid0000-0002-1331-5365
dc.authorid0000-0001-5429-1323
dc.authorid0000-0002-0716-8602
dc.authorid0000-0002-4576-128X
dc.authorid0000-0003-2428-5170
dc.contributor.authorBaşaran, Özcan
dc.contributor.authorDoğan, Volkan
dc.contributor.authorMert, Kadir Uğur
dc.contributor.authorÖzlek, Bülent
dc.contributor.authorÖzlek, Eda
dc.contributor.authorÇelik, Oğuzhan
dc.contributor.authorİnci, Sinan
dc.contributor.authorÇil, Cem
dc.date.accessioned2023-02-23T11:09:12Z
dc.date.available2023-02-23T11:09:12Z
dc.date.issued2023
dc.departmentTıp Fakültesi
dc.description.abstractBackground: The recent 2019 European Society of Cardiology/European Atherosclerosis Society practice guidelines introduced a new risk categorization for patients with diabetes. We aimed to compare the implications of the 2016 and 2019 European Society of Cardiology/European Atherosclerosis Society guidelines with regard to the lipid-lowering treatment use, low-density lipoprotein cholesterol goal attainment rates, and the estimated proportion of patients who would be at goal in an ideal setting. Methods: Patients with diabetes were classified into 4 risk categories according to 2019 European Society of Cardiology/European Atherosclerosis Society dyslipidemia guidelines from the database of EPHESUS (cross-sectional, observational, countrywide registry of cardiology outpatient clinics) study. The use of lipid-lowering treatment and low-density lipoprotein cholesterol goal attainment rates were then compared according to previous and new guidelines. Results: This analysis included a total of 873 diabetic adults. Half of the study population (53.8%) were on lipid-lowering treatment and almost one-fifth (19.1%) were on high-intensity statins. While low-density lipoprotein cholesterol goal was achieved in 19.5% and 7.5% of patients, 87.4% and 69.6% would be on target if their lipid-lowering treatment was intensified according to 2016 and 2019 European Society of Cardiology/European Atherosclerosis Society lipid guidelines, respectively. The new target <55 mg/dL could only be achieved in 2.2% and 8.1% of very high-risk primary prevention and secondary prevention patients, respectively. Conclusion: The control of dyslipidemia was extremely poor among patients with diabetes. The use of lipid-lowering treatment was not at the desired level, and high-intensity lipid-lowering treatment use was even lower. Our simulation model showed that the high-dose statin plus ezetimibe therapy would improve goal attainment; however, it would not be possible to get goals with this treatment in more than one-third of the patients.
dc.identifier.doi10.14744/AnatolJCardiol.2022.2012
dc.identifier.endpage87en_US
dc.identifier.issn2149-2263
dc.identifier.issue2en_US
dc.identifier.pmid36747449
dc.identifier.scopusqualityQ3
dc.identifier.startpage78en_US
dc.identifier.urihttps:/dx.doi.org/10.14744/AnatolJCardiol.2022.2012
dc.identifier.urihttps://hdl.handle.net/20.500.12451/10279
dc.identifier.volume27en_US
dc.identifier.wosWOS:000956673700007
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakTR-Dizin
dc.language.isoen
dc.publisherTurkish Society of Cardiology
dc.relation.ispartofAnatolian Journal of Cardiology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 United States*
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/us/*
dc.subjectDiabetes Mellitus
dc.subjectDyslipidemia
dc.subjectAtherosclerosis
dc.subjectLipid Guidelines
dc.subjectLow-density Lipoprotein Cholesterol
dc.subjectCardiovascular Risk
dc.titleHow did the updated 2019 european society of cardiology/european atherosclerosis society risk categorization for patients with diabetes affect the risk perception and lipid goals, a simulated analysis of real-life data from EPHESUS study
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
basaran-ozcan-2023.pdf
Boyut:
2.5 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Makale Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu